Rachel Koldej

1.4k total citations
59 papers, 771 citations indexed

About

Rachel Koldej is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Rachel Koldej has authored 59 papers receiving a total of 771 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 23 papers in Hematology and 16 papers in Immunology. Recurrent topics in Rachel Koldej's work include Hematopoietic Stem Cell Transplantation (15 papers), CAR-T cell therapy research (15 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Rachel Koldej is often cited by papers focused on Hematopoietic Stem Cell Transplantation (15 papers), CAR-T cell therapy research (15 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Rachel Koldej collaborates with scholars based in Australia, United States and China. Rachel Koldej's co-authors include David Ritchie, Donald S. Anson, David Parsons, Kylie M. Quinn, Andrew H. Kaye, Rodney B. Luwor, Stanley S. Stylli, D S Anson, Lynette Chee and Travis Perera and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Rachel Koldej

54 papers receiving 756 citations

Peers

Countries citing papers authored by Rachel Koldej

Since Specialization

Citations

This map shows the geographic impact of Rachel Koldej's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Koldej with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Koldej more than expected).

Fields of papers citing papers by Rachel Koldej

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Koldej. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Koldej. The network helps show where Rachel Koldej may publish in the future.

Co-authorship network of co-authors of Rachel Koldej

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Koldej. A scholar is included among the top collaborators of Rachel Koldej based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Koldej. Rachel Koldej is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study 2025 ·Blood Advances ·Allison Barraclough, Sze Ting Lee, Melinda Burgess, Leonid Churilov, Geoffrey Chong, (unknown), Michael Gilbertson, (unknown), (unknown), David Ritchie, Rachel Koldej, Andrew M. Scott, Colm Keane, Eliza A. Hawkes	0
2	Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma 2025 ·Blood Advances ·Sasanka M. Handunnetti, Amit Khot, Piers Blombery, Kate Burbury, Philip A. Thompson, David Ritchie, Rodney J. Hicks, (unknown), Rachel Koldej, Mathias Bressel, (unknown), David Westerman, Stephen Lade, Andrew W. Roberts, John F. Seymour, Constantine S. Tam, Mary Ann Anderson	0
3	Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions 2024 ·Blood ·Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Philip A. Thompson, (unknown), Mathias Bressel, (unknown), Rodney J. Hicks, David Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel Koldej, David Ritchie, Martin Dreyling, Mark A. Dawson, Sarah‐Jane Dawson, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	7
4	Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals 2024 ·Clinical & Translational Immunology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Misty R. Jenkins, Michael H. Kershaw, Anthony Jaworowski, Clare Y. Slaney, Rachel Koldej, David Ritchie, Kylie M. Quinn	1
5	A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma 2023 ·Clinical Epigenetics ·Jake Shortt, Peter Galettis, Chan Y. Cheah, Joanne E. Davis, Mandy Ludford‐Menting, Emma Link, Jennifer Martin, Rachel Koldej, David Ritchie	3
6	Spatial proteomics identifies a spectrum of immune dysregulation in acquired bone marrow failure syndromes 2023 ·Frontiers in Immunology ·Rachel Koldej, (unknown), Chin Wee Tan, Mandy Ludford‐Menting, (unknown), (unknown), Melissa J. Davis, David Ritchie	1
7	A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study 2023 ·Clinical Cancer Research ·Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, (unknown), Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, (unknown), (unknown), David Ritchie, Rachel Koldej, Benjamin Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah‐Jane Dawson, Jayesh Desai	35
8	MicroRNA profiling in aplastic anemia reveals similarities between secondary myelodysplastic syndromes arising from clonal progression and de novo MDS 2023 ·Lynette Chee, Rachel Koldej, Niko Thio, Mandy Ludford‐Menting, Lucy C. Fox, Piers Blombery, David Ritchie	1
9	Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review 2022 ·Bone Marrow Transplantation ·(unknown), Rachel Koldej, Lynette Chee, Jeff Szer, David Ritchie	3
10	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy 2021 ·Frontiers in Immunology ·(unknown), Salvatore Fiorenza, Rachel Koldej, Anthony Jaworowski, David Ritchie, Kylie M. Quinn	54
11	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study 2019 ·Blood ·Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Rodney J. Hicks, (unknown), Mathias Bressel, Juliana Di Iulio, David Westerman, Stephen Lade, Rishu Agarwal, Mark A. Dawson, Sarah‐Jane Dawson, Rachel Koldej, David Ritchie, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	25
12	Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study 2019 ·Blood ·Eliza A. Hawkes, (unknown), (unknown), Jodie Palmer, Michael MacManus, Colm Keane, Andrew M. Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, (unknown), Allison Barraclough, Sze-Ting Lee, (unknown), Rachel Koldej, Richard Khor	1
13	More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity 2018 ·Blood ·(unknown), Joanne E. Davis, Kylie D. Mason, Dale I. Godfrey, Adam P. Uldrich, Constantine S. Tam, Rachel Koldej, David Ritchie	1
14	The Impact of Vitamin D Replacement on Survival, Relapse and GvHD after Allogeneic Stem Cell Transplantation: A Matched Cohort Analysis 2018 ·Bone Marrow Transplantation ·Sara Mastaglio, Eric Wong, Travis Perera, Andrew Lim, (unknown), (unknown), Jeff Szer, (unknown), Rachel Koldej, David Ritchie	1
15	MicroRNA as potential biomarkers in Glioblastoma 2015 ·Journal of Neuro-Oncology ·(unknown), Stanley S. Stylli, Rachel Koldej, David Ritchie, Tali Siegal, Andrew Morokoff, Andrew H. Kaye, Rodney B. Luwor	43
16	Comparison of Insulators and Promoters for Expression of the Wiskott–Aldrich Syndrome Protein Using Lentiviral Vectors 2013 ·PubMed ·Rachel Koldej, (unknown), Matthew M. Wielgosz, Sheng Zhou, (unknown), Brian P. Sorrentino, Arthur W. Nienhuis	15
17	Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues 2009 ·Molecular Genetics and Metabolism ·Sharon Byers, (unknown), (unknown), Rachel Koldej, Donald S. Anson	18
18	Single‐dose lentiviral gene transfer for lifetime airway gene expression 2009 ·The Journal of Gene Medicine ·(unknown), Karlea L. Kremer, Rachel Koldej, Darren S. Miller, Donald S. Anson, David Parsons	55
19	Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. 2007 ·PubMed ·Donald S. Anson, Chantelle McIntyre, Belinda J. Thomas, Rachel Koldej, Enzo Ranieri, Ainslie L.K. Derrick‐Roberts, Peter R. Clements, Kylie R. Dunning, Sharon Byers	31
20	Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production 2005 ·The Journal of Gene Medicine ·Rachel Koldej, Patricia Cmielewski, (unknown), David Parsons, D S Anson	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact